Teitur Trophics reports Phase I safety and CNS exposure for TT-P34
Teitur Trophics has announced positive topline results from a Phase I trial of TT-P34, its lead neuroprotective peptide, in healthy volunteers and patients with early-stage Parkinson's disease (PD). The Aarhus-based company said the data confirm acceptable safety and pharmacokinetics and will underpin a Series B fundraise ahead of a planned Phase II study in 2027.
The randomised, double-blind, placebo-controlled trial was conducted at the Centre for Human Drug Research in Leiden, the Netherlands. It enrolled 55 healthy volunteers across single and multiple ascending dose cohorts, followed by 12 patients with early-stage PD. Once-weekly subcutaneous dosing was safe and well tolerated at all doses tested, with no dose-limiting findings. Crucially, the drug was also well tolerated when given alongside standard levodopa therapy in the PD cohort, a prerequisite for real-world use in a patient population already on chronic treatment.
CNS exposure and biomarker signals
Pharmacokinetic analysis confirmed that TT-P34 crosses the blood-brain barrier, producing dose-dependent exposure within the brain and central nervous system. The trial also generated a panel of mechanism-related biomarkers measurable in cerebrospinal fluid. Over the 50-day study period, the majority of PD patients who received TT-P34 showed a coordinated response across multiple lysosomal proteins in CSF, a signal the company says is consistent with modulation of the lysosomal and mitochondrial pathways the drug is designed to engage.
Andreas Borta, Chief Medical Officer at Teitur Trophics, said the biomarker data, "which indicate engagement of the lysosomal pathway, are also highly encouraging." The company is positioning TT-P34 as a potential disease-modifying agent rather than a symptomatic treatment, targeting a dual mechanism that the release describes as restoring both mitochondrial and lysosomal function. It adds that the same pathway may be relevant in frontotemporal dementia and Huntington's disease, suggesting a broader pipeline ambition beyond PD.
The Phase I dataset will be presented at the International Congress of Parkinson's Disease and Movement Disorders in Seoul on 5 October, providing the scientific community its first detailed view of the findings.
Market context and regulatory path
Disease-modifying therapy for Parkinson's remains one of the most sought-after prizes in neurology. Despite decades of research, no approved drug has demonstrated the ability to slow or halt neurodegeneration in PD; existing treatments manage symptoms without altering the underlying pathology. Teitur's claim of disease-modification potential will therefore face considerable scrutiny. Phase II design, endpoint selection, and the biomarker strategy will all draw close attention from regulators and investors alike, given the historical difficulty of translating early CNS biomarker signals into clinical benefit.
Several academic spinouts and clinical-stage companies are pursuing mechanistically distinct approaches to PD disease modification, including alpha-synuclein-targeting antibodies, LRRK2 inhibitors, and GBA-pathway modulators. A peptide-based approach targeting lysosomal and mitochondrial function simultaneously is less crowded, though the competitive landscape is subject to rapid change. The European Medicines Agency has been supportive of adaptive trial designs in neurodegenerative conditions, which may offer Teitur a degree of flexibility in its Phase II programme.
Chief executive Simon Mølgaard noted that the company is actively fundraising for its Series B to finance the Phase II study. With the trial data now available, investor conversations are likely to centre on the strength of the CSF biomarker panel as a surrogate for target engagement, and on whether the Phase II trial will be powered for a regulatory endpoint or primarily for proof of concept. No Series B size, timeline, or lead investor has been disclosed.